Healthcare Industry News: migraine
News Release - September 20, 2007
Robert S. Fishman, MD, FCCP Joins Alexza as Vice President, Medical AffairsPALO ALTO, Calif., Sept. 20 (HSMN NewsFeed) -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced today that Robert S. Fishman, MD, FCCP has joined the company as Vice President, Medical Affairs. He will have primary responsibilities in the development and execution of strategies for Alexza's multiple clinical product candidates and for medical oversight of all of our clinical programs. Dr. Fishman was most recently Senior Vice President, Clinical Development for Anthera Pharmaceuticals, Inc. He previously was Vice President, Scientific Affairs and Vice President, Clinical Operations for Aerogen, Inc., where he employed from 1998 - 2005. He was Director, Clinical Affairs for Heartport, Inc. from 1995 - 1998. Dr. Fishman was Assistant Professor of Medicine, Pulmonary and Critical Care Medicine, at Stanford University School of Medicine from 1993 - 1995. He completed a fellowship in pulmonary and critical care medicine at Massachusetts General Hospital from 1989 - 1992. Dr. Fishman holds an MD from Stanford University School of Medicine and an AB in biology from Harvard University.
"We are very pleased to welcome Bob to Alexza as a leader of our clinical development team and member of the Alexza Executive Team," said James V. Cassella, PhD, Alexza Senior Vice President, R&D. "Bob is a physician who brings a skill set to Alexza that will greatly enhance the maturation and depth of our clinical development programs. With his experience and expertise in pulmonary medicine and drug delivery, we look forward to Bob's contributions to our future growth and development."
Alexza is an emerging specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the StaccatoŽ system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug delivery through deep lung inhalation. The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience. The Company has six product candidates in development; AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic and bipolar disorder patients, AZ-001 (Staccato prochlorperazine) for the acute treatment of migraine headaches, AZ-002 (Staccato alprazolam) for the acute treatment of panic attacks associated with panic disorder, AZ-104 (Staccato loxapine) for the acute treatment of migraine headaches, AZ-003 (Staccato fentanyl) for the treatment of patients with acute pain and AZ-007 (Staccato zaleplon) for the treatment of sleep disorder in patients who have difficulty falling asleep.
Safe Harbor Statement
This press release includes forward-looking statements regarding growth of the Company's product candidate pipeline and development of the Company's product candidates. Any statement describing the Company's expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs. The Company's forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning Alexza's business are described in additional detail in the Company's Annual Report on Form 10-K/A for the year ended December 31, 2006, and the Company's other Periodic and Current Reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and we undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
Source: Alexza Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.